Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of luxdegalutamide plus lutetium (177Lu) vipivotide tetraxetan versus lutetium (177Lu) vipivotide tetraxetan alone in PSMA-positive metastatic castration-resistant prostate cancer
NL-OMON60669Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of luxdegalutamide and lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Novartis. Primary endpoints: PSA50 rate, Safety and 1 more. Started Dec 2025; status: active, not recruiting.
02
Drugs
luxdegalutamidelutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON60669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60669.